Abstract Details

Title COVID-19 Antibody Response by Vaccine Type and Lymphocyte Count in RMS Patients on Ponesimod: Results From Phase 2 Long-term Extension Study AC-058B202

Topic Multiple Sclerosis

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-003

Objective To characterize the SARS-CoV-2 humoral response by vaccine type and pre-vaccination lymphocyte count in relapsing multiple sclerosis (RMS) patients who have received coronavirus disease 2019 (COVID-19) vaccination while on ponesimod treatment.

Background Various factors may impact the humoral response to COVID-19 vaccination in MS patients treated with sphingosine 1-phosphate receptor modulators, including ponesimod.

Design/Methods Patients in the Phase 2 extension study AC-058B202 receiving ponesimod 20 mg who reported COVID-19 vaccination were included in this analysis. Blood samples collected before and ≥3 weeks after vaccination were evaluated with Human SARS-CoV-2 PreSpike IgG (spike antibody) enzyme-linked immunoassay (Nexelis). A responder to vaccination was defined as seroconversion in case of negative pre-vaccination antibody testing, or a 4-fold antibody concentration increase in case of positive pre-vaccination antibody result. Responder analysis was performed by vaccine type and by pre-vaccination lymphocyte count.

Results 49 COVID-19-vaccinated patients had both pre- and post-vaccination blood samples available for analysis and were on uninterrupted ponesimod treatment during the course of vaccination. Response to COVID-19 vaccination varied by vaccination type: of 32 participants who received mRNA vaccines, 29 (90.6%) met responder criteria. Of 7 participants who received viral vector vaccines, 5 (71.4%) were responders. Of 6 participants who received inactivated virus vaccines, 2 (33.3%) were responders. Of 4 participants who received mixed or unspecified vaccine types, 4 (100%) were responders. Response to COVID-19 vaccination also varied by lymphocyte count: of 16 participants with pre-vaccination lymphocyte count <500/mm³, 9 (56.3%) were responders. Of 32 participants with lymphocyte count ≥500/mm³, 30 (93.8%) were responders.

Conclusions Humoral response to COVID-19 vaccines in RMS patients on ponesimod in the Phase 2 study varied by vaccine type and pre-vaccination lymphocyte count. In patients who received mRNA COVID-19 vaccines and/or who had pre- vaccination lymphocyte count ≥500/mm³, most (>90%) met antibody concentration responder criteria.

Authors/Disclosures
Janice Wong, MD PRESENTER	Dr. Wong has received personal compensation for serving as an employee of Janssen Research & Development. Dr. Wong has received personal compensation for serving as an employee of Biogen. Dr. Wong has stock in Biogen. Dr. Wong has stock in Janssen Research & Development.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Tatiana Sidorenko, MD, PhD (Actelion Pharmaceuticals Ltd.)	Dr. Sidorenko has received personal compensation for serving as an employee of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical company of Johnson&Johnson. Dr. Sidorenko has stock in Johnson&Johnson.

��ɫ��

��ɫ��